<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Role of mucoactive agents and secretion clearance techniques in COPD
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Role of mucoactive agents and secretion clearance techniques in COPD
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Role of mucoactive agents and secretion clearance techniques in COPD
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Loutfi Sami Aboussouan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Umur Hatipoglu, MD, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tracheobronchial mucus contributes significantly to the symptoms of chronic obstructive pulmonary disease (COPD) and is a defining feature of the condition [
         <a href="#rid1">
          1
         </a>
         ]. Chronic mucus hypersecretion is a major cause of airflow obstruction in COPD and is associated with increased mortality, an accelerated decline of forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ), reduced quality of life, and increased risk of exacerbations and hospitalizations [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The role of mucoactive therapy in the management of COPD will be reviewed here. The role of mucoactive agents in the treatment of cystic fibrosis (CF) lung disease and non-CF bronchiectasis is discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1435.html" rel="external">
          "Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H804987757">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A mucoactive drug is defined as an agent with the capability of modifying mucus production, secretion, its nature and composition, or its interactions with the mucociliary epithelium [
         <a href="#rid3">
          3
         </a>
         ]. Examples of mucoactive drugs include expectorants (induce cough or increase the volume of secretions), mucolytics (reduce the viscosity of mucus), mucokinetic drugs (increase the mobility and transportability of mucus), and mucoregulators (control the process of hypersecretion) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PROPERTIES OF MUCUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The surface liquid covering the epithelial lining of the airways comprises at least two layers: the mucus layer (gel) and the periciliary layer surrounding the cilia [
         <a href="#rid5">
          5,6
         </a>
         ]. In contrast to traditional models where the periciliary layer is assumed to be liquid (sol), a more recent model considers it as consisting of a gel mesh of cell-tethered mucins and polysaccharides [
         <a href="#rid7">
          7
         </a>
         ]. Mucus consists of a mixture of transudative fluid and secretions from surface epithelium and submucosal glands. It is predominantly composed of water (95 percent) and glycoproteins (2 to 3 percent), with smaller components of proteoglycans (0.1 to 0.5 percent), lipids (0.3 to 0.5 percent), proteins, and DNA [
         <a href="#rid8">
          8
         </a>
         ]. The glycoprotein component consists of secreted mucins, particularly the large polymeric structures MUC5AC and MUC5B, which account for the rheologic properties (ie, properties governing flow) of mucus [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Mucus is a movable barrier that maintains hydration and contains defense factors against various pathogens [
         <a href="#rid9">
          9
         </a>
         ]. The normal volume of mucus secretion is approximately 15 mL/day [
         <a href="#rid10">
          10
         </a>
         ], with a mucociliary clearance of 50 micrometers/second [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Tracheobronchial mucus behaves as a non-Newtonian fluid with viscoelastic properties [
         <a href="#rid10">
          10
         </a>
         ]. The liquid-like, viscous properties allow the mucus to be extruded by glands, whereas the solid-like, elastic properties permit the transfer, storage, and conversion into motion of the energy imparted by the moving cilia. Glycoproteins are essential for this elasticity of mucus. A surfactant layer between the mucus gel and periciliary sol acts as a lubricant that also facilitates the transfer of energy from beating cilia to mucus [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Mucus secretion can increase three-fold in COPD and 10-fold in cystic fibrosis [
         <a href="#rid5">
          5
         </a>
         ]. Mucus composition can also change in disease states. For instance, concentrations of MUC5B and MUC5AC increase 3-fold and 10-fold respectively in ever smokers with severe COPD relative to controls [
         <a href="#rid11">
          11
         </a>
         ]. Further, DNA can contribute up to 10 percent of the dry weight of mucus secretions in cystic fibrosis [
         <a href="#rid13">
          13
         </a>
         ]. The hydration of mucus also declines with disease states, from a 95 percent normal water composition, to 90 percent in smokers, and &lt;83 percent in cystic fibrosis [
         <a href="#rid14">
          14
         </a>
         ]. A contributing factor to the dehydration of airway mucous may be internalization of the cystic fibrosis transmembrane conductance regulator (CFTR) with cigarette smoking [
         <a href="#rid14">
          14
         </a>
         ]. As the mucin concentration increases in disease states, mucociliary clearance declines, until a threshold following which adherent secretions may only be managed by cough clearance [
         <a href="#rid11">
          11
         </a>
         ]. Uncleared mucus otherwise contributes to airway obstruction and to the risk for infection [
         <a href="#rid11">
          11
         </a>
         ]. The importance of mucus secretion in the pathophysiology of disease is highlighted by the finding that total mucin concentration predicts traditionally defined chronic bronchitis, and may serve a biologic marker for this otherwise clinically defined disease [
         <a href="#rid11">
          11
         </a>
         ]. Further, mucus hypersecretion, upregulation of MUC5AC and MUC5B, cross-linking and entanglement of mucin polymers, reduced mesh network pore size, and decreased mucus clearance all contribute to airway obstruction, infection risk, and lung function decline [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         In determining the ability of an agent to promote clearance of secretions, both mucociliary clearance and cough clearance need to be addressed. Different rheologic properties have been reported to have different and potentially antagonistic effects on these two mechanisms of mucus transport. As an example, mucus clearance requires effective transfer of the kinetic energy from beating cilia to the mucus. In that regard, factors that improve mucociliary transport include: a higher mucus elasticity (to store the transmitted energy), lower mucus viscosity (to reduce loss of energy), higher adhesivity (that hinders wave formation in the gel layer), increased spinnability (a measure of the thread forming ability of mucus), increased ciliary beat frequency, a thinner mucus layer, and a periciliary (sol) layer that is just less than the height of the cilia (to improve coupling with ciliary tips) [
         <a href="#rid4">
          4,16,17
         </a>
         ].
        </p>
        <p>
         In contrast, factors that improve cough clearance include: a higher mucus viscosity, lower mucus elasticity (to reduce recoil of cough-sheared mucus), lower adhesivity (to promote wave formation in the gel), lower spinnability (ability to be spun into a thread), a thicker mucus layer, and a periciliary layer that is higher than the height of the cilia [
         <a href="#rid4">
          4,18
         </a>
         ]. However, these general concepts may not always apply across disease states. For instance, in one study of mucus transport in patients with cystic fibrosis, the elastic modulus (capacity to be deformed elastically) was found to be negatively correlated with mucociliary transport, whereas contact angle (a reflection of surface tension associated with the adhesive properties of mucus: a higher contact angle reflects poor wettability and poor adhesiveness) was negatively correlated with cough clearance [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Disease states may affect the rheological properties of mucus [
         <a href="#rid20">
          20
         </a>
         ]. For instance, the levels of the gel-forming mucins, MUC5AC and MUC5B, are elevated in the airways and sputum of individuals with chronic respiratory diseases [
         <a href="#rid11">
          11
         </a>
         ], and may contribute to the viscoelastic properties of mucus [
         <a href="#rid8">
          8
         </a>
         ]. Increased purulence of sputum results in increased viscosity, surface tension, elastic modulus, contact angle, and in decreased cough transport, but these effects may be secondary to decreased water content [
         <a href="#rid19">
          19
         </a>
         ]. Patients with asthma appear to have the highest sputum viscosity, while patients with cystic fibrosis have lower viscosity [
         <a href="#rid4">
          4
         </a>
         ]. Patients with chronic bronchitis and bronchiectasis have sputum with intermediate viscosities [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Subsequent attention has focused upon the role of the periciliary layer. Studies have shown that transport of the periciliary layer is mucus dependent. This suggests that new therapies for the treatment of excess respiratory mucus should focus on the restoration of airway surface liquid volume rather than alteration of its tonicity [
         <a href="#rid5">
          5,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H518133719">
         <span class="h1">
          MUCOACTIVE EFFECTS OF ROUTINE TREATMENTS FOR COPD
         </span>
         <span class="headingEndMark">
          —
         </span>
         In chronic obstructive pulmonary disease (COPD), the most important intervention to reduce sputum production is cigarette smoking cessation [
         <a href="#rid22">
          22
         </a>
         ]. Some routine therapies for COPD, in addition to their bronchodilator or anti-inflammatory effects, also have mucoactive effects.
        </p>
        <p>
         Bronchodilators act as mucokinetic agents by improving airflow and facilitating mucus clearance. The different types of bronchodilators have additional, more specific effects that may be either beneficial or detrimental.
        </p>
        <p class="headingAnchor" id="H518134563">
         <span class="h2">
          Beta agonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Beta agonists improve clearance of airway mucus largely via an effect on ciliary beat frequency. As an example, aerosolized
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         (a potent sympathomimetic amine with almost exclusive beta-adrenergic activity) increases mucus clearance, presumably from increased ciliary beat rate [
         <a href="#rid23">
          23
         </a>
         ]. This effect is not due to bronchial vasodilation, the presence of aqueous aerosol droplets, reflex parasympathetic activation, or bronchodilation [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Anticholinergics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The anticholinergic agent
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         is an effective antisialagogue (reduces saliva secretion) that results in significant reductions in tracheal mucus velocity and mucociliary transport [
         <a href="#rid25">
          25,26
         </a>
         ]. However, it has no effect on mucus secretory rate [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          Ipratropium
         </a>
         bromide does not appear to have the same effects as
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         . As an example, studies in humans have not detected changes in the clearance of secretions or in sputum volume or viscosity [
         <a href="#rid27">
          27
         </a>
         ], while animal studies have shown only minimal depression of ciliary beat frequency and tracheal mucus velocity, with no effect on volume or viscoelastic properties [
         <a href="#rid25">
          25
         </a>
         ]. Thus, ipratropium bromide can improve airway obstruction without negatively affecting mucociliary clearance [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         In small studies, the effect of
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         on mucociliary clearance (as measured by radioaerosol clearance) was not different from placebo, but tiotropium was inferior to
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          formoterol
         </a>
         [
         <a href="#rid28">
          28,29
         </a>
         ]. It is not known whether this is a clinically important effect.
        </p>
        <p class="headingAnchor" id="H518134588">
         <span class="h2">
          Methylxanthines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methylxanthines (eg,
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         ) stimulate ciliary beat frequency and increase water flux toward the lumen, which should improve mucus clearance, but they also increase mucus secretion in the lower airways [
         <a href="#rid30">
          30
         </a>
         ]. However, some of these effects depend on a relatively high dose that causes gastric irritation (and thus a vagally-mediated increase in airway secretions), rather than on the bronchodilator effect. Overall, oral
         <a class="drug drug_general" data-topicid="8620" href="/z/d/drug information/8620.html" rel="external">
          aminophylline
         </a>
         increases tracheobronchial mucociliary clearance in patients with COPD, but this effect is not associated with identifiable improvement in pulmonary function or cough [
         <a href="#rid31">
          31
         </a>
         ]. The role of methylxanthines in COPD is more related to improvement in exercise tolerance than to improved secretion clearance or reduction in the frequency of exacerbations.
        </p>
        <p class="headingAnchor" id="H518134594">
         <span class="h2">
          Phosphodiesterase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The phosphodiesterase (PDE)4 inhibitor
         <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">
          roflumilast
         </a>
         , although not a mucoactive agent, was found to be most effective in patients with repeated exacerbations of COPD and with a chronic bronchitis phenotype, consisting of high cough or sputum scores [
         <a href="#rid32">
          32
         </a>
         ]. Randomized trials have confirmed that the use of roflumilast in such patients reduced the exacerbation frequency, improved the FEV
         <sub>
          1
         </sub>
         , and improved the dyspnea scores [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Inhaled glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids can act as a mucoregulator by affecting the underlying cause of mucus hypersecretion. Aerosolized
         <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">
          beclomethasone
         </a>
         at doses &gt;800 mcg/day has been shown to produce a significant improvement in spirometry in patients with chronic bronchitis [
         <a href="#rid34">
          34
         </a>
         ]. The benefit appears to result from control of airway inflammation since beclomethasone does not affect mucociliary clearance [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1449.html" rel="external">
          "Role of inhaled glucocorticoid therapy in stable COPD"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H518134601">
         <span class="h1">
          MUCOACTIVE STRATEGIES FOR SELECTED PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Types of mucoactive agents that may be helpful in selected patients with refractory symptoms include systemic antibiotics and thiol preparations (eg,
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         , erdosteine, carbocysteine).
        </p>
        <p class="headingAnchor" id="H518133576">
         <span class="h2">
          Antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain antibiotics are thought to have mucoactive effects beyond their antimicrobial effects. Potential mechanisms of action may include inhibition of proinflammatory cytokines or immunomodulation of antiinflammatory effects [
         <a href="#rid36">
          36-38
         </a>
         ].
        </p>
        <p>
         An indirectly mucoactive effect is seen in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) associated with changes in sputum volume or color, when antibiotics are used to reduce the bacterial load that contributes to inflammation and increased sputum production. (See
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management", section on 'Antiviral and antimicrobial agents'
         </a>
         .)
        </p>
        <p>
         In addition, macrolide antibiotics may have an anti-inflammatory effect that reduces mucus secretion independent of antimicrobial activity [
         <a href="#rid36">
          36
         </a>
         ]. A possible example of this anti-inflammatory effect is the beneficial effect of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         in diffuse panbronchiolitis, a disease with copious sputum production, at doses below those usually considered antimicrobial. (See
         <a class="medical medical_review" href="/z/d/html/4366.html" rel="external">
          "Diffuse panbronchiolitis", section on 'Erythromycin'
         </a>
         .)
        </p>
        <p>
         Macrolide and fluoroquinolone antibiotics have been found to reduce the frequency of exacerbations in certain patients with COPD, although careful patient selection and monitoring are needed to reduce adverse effects. (See
         <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">
          "Management of infection in exacerbations of chronic obstructive pulmonary disease", section on 'Prophylactic macrolides'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">
          "Management of refractory chronic obstructive pulmonary disease", section on 'Macrolides and other chronic antibiotic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Thiols and thiol derivatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agents that sever disulfide bridges (eg, N-acetyl-L-cysteine (aka
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          acetylcysteine
         </a>
         or NAC), S-carboxymethyl cysteine (carbocysteine), 2-mercaptoethane sulfonate, and erdosteine) act directly on mucoproteins, liquefying mucus and lowering its viscosity. In addition, they may have other potentially relevant antioxidant, anti-inflammatory, and antibacterial properties [
         <a href="#rid10">
          10,39,40
         </a>
         ]. Recommendations from systematic reviews and clinical guidelines regarding mucolytics are predominantly based on this class of agents [
         <a href="#rid1">
          1,41,42
         </a>
         ].
        </p>
        <p>
         Side effects of thiol preparations include nausea, vomiting, and allergic reactions.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          N-acetylcysteine (NAC)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         liquefies mucus and DNA (via disruption of disulfide bonds) and has antioxidant effects when used at an adequate dose. However, given the small and inconsistently demonstrated clinical benefits and the potential for adverse effects, we do not routinely use oral NAC in patients with COPD.
        </p>
        <p>
         In a systematic review, mucolytics (strongly represented by NAC in the trials analyzed) resulted in one fewer exacerbation every three years, reduced disability by 0.43 days per participant per month, and had a small favorable effect on quality of life that did not reach the minimally clinically important difference [
         <a href="#rid41">
          41
         </a>
         ]. Trials specifically examining the effects of oral NAC in patients with COPD have yielded conflicting results [
         <a href="#rid43">
          43-52
         </a>
         ] and do not show benefit in a meta-analysis [
         <a href="#rid53">
          53
         </a>
         ]; however, there is more consistent evidence of benefit in trials using high doses of oral NAC:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Placebo-controlled study on efficacy and safety of
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysTeine
         </a>
         High-dose in Exacerbations of chronic Obstructive pulmoNary disease (PANTHEON) trial randomly assigned 1006 Chinese patients with moderate to severe COPD (forced expiratory volume in one second [FEV
         <sub>
          1
         </sub>
         ] of 30 to 70 percent of predicted) to NAC (600 mg) or placebo, twice daily for one year [
         <a href="#rid54">
          54
         </a>
         ]. A reduction in exacerbations was noted in the NAC group (risk ratio 0.78, 95% CI 0.67-0.90), but pulmonary function and quality of life were not significantly different between the groups. However, certain features of the trial limit the conclusions that can be drawn: Exacerbations were assessed by diary cards and may have been underreported; patients requiring supplemental oxygen or pulmonary rehabilitation were excluded from the trial; approximately 40 percent of the study population were nonsmokers; and 25 percent of participants did not complete the study.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a one-year trial that randomly assigned 120 patients with moderately severe COPD to high-dose NAC (1200 mg per day) or placebo, no significant improvement occurred in exercise capacity or quality of life, but the frequency of exacerbations was decreased with NAC compared with placebo (0.96 times/y versus 1.71 times/y, p = 0.019) [
         <a href="#rid55">
          55
         </a>
         ]. Modest improvements were noted in the mid-expiratory flow rate (forced expiratory flow [FEF] 25 to 75 percent), but not FEV
         <sub>
          1
         </sub>
         . The majority of those patients (&gt;70 percent) were on inhaled glucocorticoids, raising the possibility that concurrent glucocorticoids blunted the effect of NAC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a network meta-analysis of randomized trials assessing mucolytics in COPD, high-dose NAC (1200 mg per day) protected against exacerbations when compared with placebo (odds ratio 0.56, 95% CI 0.35–0.92), whereas lower dose NAC (600 mg per day) did not [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Reasons for the discrepancy between the various studies may include a dose dependent effect of NAC (eg, lack of antioxidant properties at doses under 1200 mg daily), poor penetration into bronchoalveolar fluid when administered orally, and reduced effect in patients on inhaled glucocorticoids [
         <a href="#rid55">
          55,57
         </a>
         ]. Doses of NAC up to 3000 mg per day were considered to be safe and well tolerated, with a similar safety profile regardless of dose [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         In early studies, NAC was administered via inhalation or direct instillation during bronchoscopy, as NAC causes liquefaction of mucus within one minute of direct application with a maximal effect at five to ten minutes [
         <a href="#rid59">
          59
         </a>
         ]. However, nebulized NAC can cause cough or acute bronchospasm, so it is often coadministered with a beta-adrenergic agonist [
         <a href="#rid58">
          58,60
         </a>
         ]. Due to the combined use of NAC and the beta agonist, it is difficult to know whether any beneficial effects on mucociliary clearance are attributable to the nebulized NAC independent from the beta-agonist [
         <a href="#rid61">
          61
         </a>
         ]. NAC can also be nebulized together with bromelain (a protease enzyme found in the stem of pineapples) with reduction in viscosity and improved flow of experimental sputum compared to either agent alone [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">
          "Management of refractory chronic obstructive pulmonary disease", section on 'Mucoactive agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Erdosteine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erdosteine is another thiol agent with an established safety profile and generally fewer gastrointestinal side effects than other thiol derivatives. Where available, erdosteine may be an option for the management of frequent COPD exacerbations in patients who are unable to use inhaled glucocorticoids with long-acting beta agonists or long-acting muscarinic agents. However, evidence is mixed regarding reduction in exacerbations and degree of effect when used as add-on therapy to more established inhaled regimens [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The EQUALIFE study, a randomized trial of 155 patients with COPD, demonstrated that compared with placebo, treated patients had a 30 percent reduction in exacerbations, a 58 percent reduction in hospital days, improved health status, and lower COPD-related diseases costs [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a separate placebo-controlled trial in 445 patients with moderate and severe COPD (the RESTORE trial), addition of erdosteine to usual care decreased the rate of mild exacerbations but not moderate or severe exacerbations [
         <a href="#rid64">
          64
         </a>
         ]. Erdosteine also reduced the exacerbation duration regardless of exacerbation severity but did not improve quality of life as measured by the St. George's Respiratory Questionnaire. A post hoc analysis showed similar findings in the subset of patients with moderate (not severe) COPD [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis indirectly comparing mucolytic treatments in 2753 patients with COPD from seven trials, erdosteine was more effective than carbocysteine and NAC in reducing acute exacerbation number, duration, and associated hospitalizations [
         <a href="#rid66">
          66
         </a>
         ]. According to this analysis, one exacerbation could be prevented for every ten patients treated for one year with erdosteine.
        </p>
        <p>
        </p>
        <p>
         In addition to its mucolytic properties, erdosteine may have anti-inflammatory properties with reduced levels of leukotriene (LT) B4 and markers of oxidative stress demonstrated in one study of active smokers with COPD [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Carbocysteine
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the Chinese PEACE study, 709 patients with moderate-to-severe COPD were randomized in a double-blind trial to receive 500 mg carbocysteine (S-carboxymethyl cysteine) or placebo, three times a day for 12 months [
         <a href="#rid68">
          68
         </a>
         ]. Compared to placebo, patients on carbocysteine had a 0.34 mean reduction in exacerbations per patient per year (1.35 versus 1.01 respectively). Quality of life as measured by the St. George's Respiratory Questionnaire was also significantly improved at 12 months.
        </p>
        <p>
         Where available, carbocysteine may be an option for the management of frequent COPD exacerbations in patients who are unable to use inhaled glucocorticoids with long-acting beta agonists or long-acting muscarinic agents. However, there is no clear evidence that these agents effectively reduce exacerbations when used as add-on therapy to more established inhaled regimens [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Role of concomitant inhaled glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data are conflicting regarding whether mucolytic thiol derivatives confer additional benefits in patients already on inhaled glucocorticoids (ICS) in addition to those who are ICS-naive [
         <a href="#rid48">
          48,54,55
         </a>
         ]. The following are the major trials that have examined this issue:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The PANTHEON trial, which randomly assigned 1006 patients with COPD to oral
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         (1200 mg/day) or placebo, stratified the randomization based on use of ICS such that approximately half the subjects were using ICS [
         <a href="#rid54">
          54,69
         </a>
         ]. As noted above, a reduction in the frequency of exacerbations was noted in the NAC group, but no benefits were noted in pulmonary function or quality of life. No interaction was noted between the effect on exacerbations and the use of ICS, suggesting that patients on ICS also experienced a reduction in exacerbations. The trial did not provide the dose of ICS used by the study subjects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Chinese PEACE trial (709 subjects), which found an overall reduction in exacerbations with carbocysteine compared with placebo, did not find a significant interaction on reduction of exacerbations between concomitant use of ICS and carbocysteine [
         <a href="#rid68">
          68
         </a>
         ]. However, only 17 percent of PEACE study participants received ICS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the BRONCUS trial (523 subjects), a reduction in exacerbations with
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         was only noted in the subgroup of patients who were not using ICS, which comprised 40 percent of the subjects [
         <a href="#rid48">
          48
         </a>
         ]. However, this trial used half the dose of NAC compared with the other two trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the RESTORE trial of erdosteine (445 subjects) the randomization was stratified by used of ICS, but there was no significant difference in the exacerbation rate or duration in those taking ICS relative to those who did not [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="local">
          'Erdosteine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H518134549">
         <span class="h1">
          MUCOACTIVE AGENTS OF LIMITED OR NO BENEFIT
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of modalities, including hydration, hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         inhalation, oral expectorants, oral iodide preparations, cromoglycate, and inhalation of
         <a class="drug drug_general" data-topicid="9385" href="/z/d/drug information/9385.html" rel="external">
          DNase
         </a>
         , have been utilized to alter the characteristics of mucus, but without evidence of substantial clinical efficacy.
        </p>
        <p class="headingAnchor" id="H518134111">
         <span class="h2">
          Hydration
         </span>
         <span class="headingEndMark">
          —
         </span>
         While maintaining normal hydration is appropriate, there is no evidence that overhydration in order to facilitate sputum production is of any benefit. One study, for example, evaluated the effect of hydration on mucus volume, viscoelastic properties of sputum, respiratory symptoms, and forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ): there were no differences when patients were dehydrated, were treated with hydration (1800 to 2400 mL/day), or had ad lib fluid intake [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H518134117">
         <span class="h2">
          Hypertonic saline
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         aerosols have traditionally been used to induce expectoration of sputum for diagnostic evaluation [
         <a href="#rid71">
          71
         </a>
         ]. The effects of hypertonic saline that aid the clearance of sputum include [
         <a href="#rid39">
          39,72,73
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stimulation of a productive cough
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased sputum spinnability (ability to be spun into a strand)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased sputum viscoelasticity
        </p>
        <p>
        </p>
        <p>
         Despite these effects and the benefits in cystic fibrosis, there is no evidence of any therapeutic value of hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         aerosols in chronic obstructive pulmonary disease (COPD) [
         <a href="#rid73">
          73-75
         </a>
         ]. In the more specific setting of chronic bronchitis, 7 percent hypertonic saline restored mucus clearance to the normal range [
         <a href="#rid14">
          14
         </a>
         ] but did not improve spirometry or patient outcomes compared with hypotonic control after two weeks [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         In addition, the administration of either isotonic or hypertonic aerosols can induce a significant decrease in lung function in patients with COPD due to bronchoconstriction [
         <a href="#rid77">
          77
         </a>
         ]. This deleterious effect may be mast cell-mediated, since the decrease in lung function was most pronounced in patients with increased histamine in their sputum. In an eight-week COPD rehabilitation program, with random assignment of 68 patients to either isotonic or hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         aerosols prior to the exercise sessions, the improvement in six-minute walking distance at conclusion of the program was greater in those receiving isotonic saline, and adverse effects of cough and bronchoconstriction were greater in the hypertonic saline group [
         <a href="#rid78">
          78
         </a>
         ]. Both groups had equivalent improvement in quality of life. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Inhaled airway clearance agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H518134123">
         <span class="h2">
          Oral expectorants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral expectorants, such as
         <a class="drug drug_general" data-topicid="8503" href="/z/d/drug information/8503.html" rel="external">
          guaifenesin
         </a>
         , bromhexine and its metabolite ambroxol, ipecac, and ammonium salts stimulate the gastric nerve and promote a vagally-mediated increase in airway secretions [
         <a href="#rid10">
          10
         </a>
         ]. As a corollary, all of these agents are actually emetics [
         <a href="#rid79">
          79
         </a>
         ]. Other mechanisms of action may include a reduction in mucus viscosity [
         <a href="#rid10">
          10
         </a>
         ] or an enhancement of the mucociliary elevator [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Despite these mucolytic actions, the limited clinical trial data available provide little evidence that oral expectorants improve lung function or subjective well-being in COPD [
         <a href="#rid10">
          10,39
         </a>
         ]. In one study, for example, both bromhexine and
         <a class="drug drug_general" data-topicid="8503" href="/z/d/drug information/8503.html" rel="external">
          guaifenesin
         </a>
         improved tracheobronchial clearance but did not change lung function, the frequency of cough, emotional well-being, or the weight and content of sputum [
         <a href="#rid39">
          39
         </a>
         ]. In a 12-month randomized trial (the AMETHIST trial) that included 242 patients with COPD (FEV
         <sub>
          1
         </sub>
         60 to 80 percent of predicted), oral ambroxol did not reduce exacerbations of COPD, except in a subgroup of subjects with the most severe symptoms (consisting of cough frequency, expectoration and dyspnea) [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H518134129">
         <span class="h2">
          Iodide preparations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iodide acts as a mucolytic by decreasing the viscosity of mucus, facilitating the breakdown of proteins by proteolytic enzymes, and increasing ciliary beat frequency [
         <a href="#rid81">
          81
         </a>
         ]. Iodine preparations include saturated solution of potassium iodide (SSKI), domiodol, and iodopropylidene glycerol. Due to their adverse effect profile, they are not recommended for use as mucolytic agents in COPD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SSKI may decrease the viscosity of mucus, but its use is limited by side effects such as a metallic taste, rash, hyperkalemia (in patients with renal insufficiency), and hypothyroidism, particularly if use is prolonged for more than six weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Domiodol is an organic iodinated mucolytic agent. When administered to tracheostomized patients after laryngectomy, this agent improved cough intensity, sputum quantity and quality, as well as ease of expectoration [
         <a href="#rid82">
          82
         </a>
         ]. It is not available for clinical use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iodopropylidene glycerol has been shown to enhance tracheobronchial clearance and mucociliary transport in expectorating patients with chronic bronchitis [
         <a href="#rid81">
          81
         </a>
         ]. In addition, a randomized, double-blind placebo-controlled study documented improvements in cough, ease of expectoration, and well-being, and a decreased duration of exacerbations [
         <a href="#rid83">
          83
         </a>
         ]. However, in a subsequent randomized, cross-over study, the use of iodinated glycerol for 16 weeks did not improve pulmonary function, wellbeing, or sputum viscoelasticity or clearability [
         <a href="#rid84">
          84
         </a>
         ]. This drug is no longer available in the United States after concerns were raised about carcinogenesis in selected strains of rats and mice.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H518134135">
         <span class="h2">
          Sodium cromoglycate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sodium cromoglycate can improve the depressed tracheal mucus velocity in asthmatics [
         <a href="#rid85">
          85
         </a>
         ]. However, the clinical significance of this finding is uncertain, and sodium cromoglycate has limited availability.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Recombinant human DNase
         </span>
         <span class="headingEndMark">
          —
         </span>
         DNA released by leukocytes is thought to contribute significantly to the viscosity of mucus in patients with cystic fibrosis (CF). Thus, recombinant human
         <a class="drug drug_general" data-topicid="9385" href="/z/d/drug information/9385.html" rel="external">
          DNase
         </a>
         is considered a mucokinetic agent that may produce improvement in pulmonary function in patients with clinically stable CF. However, recombinant human DNase does not appear to be effective in the management of non-CF bronchiectasis, and data are lacking regarding its use in COPD. A phase III trial of DNase in hospitalized COPD patients was stopped early because of lack of demonstrable benefit in interim analyses and a trend towards a higher 90-day mortality in the treatment group [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Inhaled airway clearance agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health", section on 'Mucolytic agents and airway hydration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H518133760">
         <span class="h1">
          EXPERIMENTAL MUCOACTIVE AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several agents that are mucoactive in the laboratory are being evaluated for clinical use.
        </p>
        <p class="headingAnchor" id="H3656322477">
         <span class="h2">
          Novel mucolytics
         </span>
         <span class="headingEndMark">
          —
         </span>
         A particular disadvantage of current mucolytics is their limited ability to break covalent disulfide bonds. A novel phosphine compound (P3001) is a rapidly-acting reducing agent with lower acid dissociation constant (pKa), higher reduction potential, and increased duration of action compared with N-acetyl cysteine. In in-vitro studies, P3001 decreased MUC5B and spinnability in COPD sputum significantly more than
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         [
         <a href="#rid87">
          87
         </a>
         ]. In small animal transgenic models, P3001 and MUC-031 (another novel thiol-saccharide mucolytic) reduced in vivo airway mucous; MUC-031 also improved mouse survival [
         <a href="#rid87">
          87,88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Surfactant
         </span>
         <span class="headingEndMark">
          —
         </span>
         A surfactant layer is present between layers of mucus gel and periciliary sol fluid, serving to separate these two layers and to facilitate mucus spreading [
         <a href="#rid6">
          6,12
         </a>
         ]. The lubricant properties of surfactant also promote the transfer of energy from beating cilia to mucus [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Properties of mucus'
         </a>
         above.)
        </p>
        <p>
         Several observations suggest a potential role for surfactant as a mucoactive substance, although this use of surfactant remains experimental:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A decrease in surface-active phospholipid fractions in the sputum of patients with cystic fibrosis (CF; compared with sputum from patients with chronic obstructive pulmonary disease [COPD]) has been found to correlate with increased mucus stasis [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tracheal instillation of surfactant in anesthetized dogs significantly increases ciliary beat frequency compared to instillation of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One randomized, double-blind study of 66 patients with stable chronic bronchitis compared the effectiveness of two weeks of thrice daily, nebulized phosphatidylcholine surfactant (Exosurf) versus placebo [
         <a href="#rid91">
          91
         </a>
         ]. The treatment group had increased in vitro sputum transportability, improvement in pre- and postbronchodilator forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) and forced vital capacity (FVC) by &gt;10 percent, and mildly decreased residual volume (RV)/total lung capacity (TLC) ratios. The high cost of exogenous surfactant precludes its routine use in patients with chronic bronchitis until its salutary effects are better defined in larger trials.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          MECHANICAL DEVICES TO IMPROVE MUCUS CLEARANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest physiotherapy devices, such as oral oscillating devices, high frequency chest wall oscillating devices (HFCWO), external percussion vests, and intrapulmonary percussive ventilation, have been the cornerstone of secretion removal in cystic fibrosis and other forms of bronchorrhea, although data in support of their use in chronic obstructive pulmonary disease (COPD) is limited. We occasionally use oscillating devices (eg, flutter or Acapella devices) for patients with COPD who have tenacious or copious sputum. Patients breathe in and out through the device for several larger than tidal volume breaths and then expectorate any sputum that has been raised.
        </p>
        <p>
         Several small trials have examined oscillatory devices [
         <a href="#rid92">
          92-98
         </a>
         ]. Systematic reviews of these studies have suggested that use of oscillatory devices may reduce exacerbations (rate ratio 0.50; CI, 0.30-0.83 based on three trials) [
         <a href="#rid99">
          99
         </a>
         ], improve symptom burden (COPD assessment test improvement 6.5 points, 95% CI 5.0-8.1 based on four trials) [
         <a href="#rid99">
          99
         </a>
         ], and increase exercise tolerance (mean difference in six-minute walk distance 50 meters, 95% CI 14-86 based on four trials) [
         <a href="#rid100">
          100
         </a>
         ] in patients with stable moderate to severe COPD, but the quality of the evidence is low to moderate due to incomplete blinding and variability among devices and outcomes.
        </p>
        <p>
         Devices that achieve airflow oscillation have favorable effects on the viscoelasticity of sputum both in vivo and in vitro and increase mucus movement [
         <a href="#rid101">
          101-103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1535539089">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">
          "Society guideline links: Chronic obstructive pulmonary disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4649.html" rel="external">
          "Patient education: Chronic obstructive pulmonary disease (COPD) (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4647.html" rel="external">
          "Patient education: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Burden of mucus in COPD
         </strong>
         – Increased tracheobronchial mucus is associated with increased mortality, an accelerated decline in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ), and an increased risk of hospitalization in COPD. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Properties of mucus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effect of routine therapies
         </strong>
         – General recommendations for treating excess mucus in COPD focus on the treatment of underlying airways obstruction, airway inflammation, and mucus production by the use of cigarette smoking cessation and guideline-based use of bronchodilator therapy and inhaled glucocorticoids, as well as the occasional use of methylxanthines or phosphodiesterase-4 inhibitors. (See
         <a class="local">
          'Mucoactive effects of routine treatments for COPD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other pharmacologic mucoactive therapies with evidence of benefit
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Short-term and long-term antibiotics
         </strong>
         – Antibiotic therapy helps in acute exacerbations of COPD associated with increased sputum volume or purulence by reducing the bacterial load that contributes to inflammation and sputum production. In addition, long-term antibiotic therapy may reduce the rate of exacerbations among selected patients who have more than two exacerbations a year. (See
         <a class="local">
          'Antibiotics'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management", section on 'Antiviral and antimicrobial agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thiols and thiol derivatives
         </strong>
         – We do not routinely use oral thiol preparations in patients with COPD to treat sputum production or to prevent exacerbations. However, for patients with bothersome sputum production that is refractory to smoking cessation, routine therapies for COPD, and a course of antibiotics (when indicated), therapy with an oral thiol preparation (eg, N-acetyl cysteine [NAC], 600 mg twice daily) can be initiated on a trial basis and continued if there is symptomatic improvement. Side effects of thiol preparations include nausea, vomiting, and allergic reactions. We avoid nebulized NAC due to the potential for acute bronchospasm. (See
         <a class="local">
          'Thiols and thiol derivatives'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapies without evidence of benefit
         </strong>
         – While over-hydration provides no benefit in sputum clearance for patients with COPD, avoiding dehydration is appropriate. Modalities, such as hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         inhalation, oral expectorants (eg,
         <a class="drug drug_general" data-topicid="8503" href="/z/d/drug information/8503.html" rel="external">
          guaifenesin
         </a>
         ), oral iodide preparations (eg, saturated solution of potassium iodide [SSKI]), inhaled cromoglycate, and inhalation of
         <a class="drug drug_general" data-topicid="9385" href="/z/d/drug information/9385.html" rel="external">
          DNase
         </a>
         , may alter the characteristics of mucus but lack substantial evidence of clinical efficacy. (See
         <a class="local">
          'Mucoactive agents of limited or no benefit'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Future pharmacologic approaches
         </strong>
         – Future therapies may include agents that decrease sputum adhesiveness or viscosity and/or decrease sputum production, such as novel mucolytics or surfactants. (See
         <a class="local">
          'Experimental mucoactive agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of mechanical devices
         </strong>
         – Oscillating (eg, flutter valve, acapella device) and other mechanical devices have been used in bronchiectasis to aid in airway clearance. It is not known whether such therapy would be beneficial in patients with COPD. We occasionally use oscillating devices for patients with COPD who have tenacious or copious sputum. (See
         <a class="local">
          'Mechanical devices to improve mucus clearance'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tian PW, Wen FQ. Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease. J Transl Int Med 2015; 3:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Task Group on Mucoactive Drugs. Chest 1994; 106:1532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007; 52:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randell SH, Boucher RC, University of North Carolina Virtual Lung Group. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006; 35:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin BK. Physiology of airway mucus clearance. Respir Care 2002; 47:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Button B, Cai LH, Ehre C, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012; 337:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams OW, Sharafkhaneh A, Kim V, et al. Airway mucus: From production to secretion. Am J Respir Cell Mol Biol 2006; 34:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 2008; 70:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson PS, Phipps RJ. The anatomy, physiology, pharmacology and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease. Pharmacol Ther B 1978; 3:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kesimer M, Ford AA, Ceppe A, et al. Airway Mucin Concentration as a Marker of Chronic Bronchitis. N Engl J Med 2017; 377:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgenroth K, Bolz J. Morphological features of the interaction between mucus and surfactant on the bronchial mucosa. Respiration 1985; 47:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clunes LA, Davies CM, Coakley RD, et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 2012; 26:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pangeni R, Meng T, Poudel S, et al. Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers. Int J Pharm 2023; 634:122661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen TM, Dulfano MJ. Mucus viscoelasticity and mucociliary transport rate. J Lab Clin Med 1978; 91:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puchelle E, Zahm JM. Influence of rheological properties of human bronchial secretions on the ciliary beat frequency. Biorheology 1984; 21:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King M, Zahm JM, Pierrot D, et al. The role of mucus gel viscosity, spinnability, and adhesive properties in clearance by simulated cough. Biorheology 1989; 26:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deneuville E, Perrot-Minot C, Pennaforte F, et al. Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients. Am J Respir Crit Care Med 1997; 156:166.
          </a>
         </li>
         <li class="breakAll">
          Yeates DB. Mucus rheology. In: The Lung. Scientific Foundations, Crystal RG, West JB (Eds), Raven Press, New York 1991.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsui H, Randell SH, Peretti SW, et al. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest 1998; 102:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster WM, Bergofsky EH, Bohning DE, et al. Effect of adrenergic agents and their mode of action on mucociliary clearance in man. J Appl Physiol 1976; 41:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster WM, Bergofsky EH. Airway mucus membrane: effects of beta-adrenergic and anticholinergic stimulation. Am J Med 1986; 81:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanner A. Effect of ipratropium bromide on airway mucociliary function. Am J Med 1986; 81:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annis P, Landa J, Lichtiger M. Effects of atropine on velocity of tracheal mucus in anesthetized patients. Anesthesiology 1976; 44:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RG, Pavia D, Agnew JE, et al. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax 1986; 41:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004; 125:1726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer T, Reitmeir P, Brand P, et al. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD. Respir Med 2011; 105:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanner A. Effects of methylxanthines on airway mucociliary function. Am J Med 1985; 79:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton PP, Pavia D, Bateman JR, Clarke SW. The effect of oral aminophylline on lung mucociliary clearance in man. Chest 1981; 80:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res 2011; 12:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992; 146:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fazio F, Lafortuna CL. Beclomethasone dipropionate does not affect mucociliary clearance in patients with chronic obstructive lung disease. Respiration 1986; 50:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008; 31:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke SW, Thomson ML, Pavia D. Effect of mucolytic and expectorant drugs on tracheobronchial clearance in chronic bronchitis. Eur J Respir Dis Suppl 1980; 110:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pace E, Cerveri I, Lacedonia D, et al. Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action. Pharmaceutics 2022; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2019; 5:CD001287.
          </a>
         </li>
         <li class="breakAll">
          National Clinical Guideline Centre. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Nice guideline (published 5 December 2018). www.nice.org.uk/guidance/ng115 (Accessed on October 10, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuin R, Palamidese A, Negrin R, et al. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005; 25:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parr GD, Huitson A. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest 1987; 81:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black PN, Morgan-Day A, McMillan TE, et al. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulm Med 2004; 4:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee. Thorax 1985; 40:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millar AB, Pavia D, Agnew JE, et al. Effect of oral N-acetylcysteine on mucus clearance. Br J Dis Chest 1985; 79:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cotgreave IA, Eklund A, Larsson K, Moldéus PW. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur J Respir Dis 1987; 70:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen Y, Cai W, Lei S, Zhang Z. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD 2014; 11:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang C, Kuo S, Lin L, Yang Y. The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis. Ther Adv Respir Dis 2023; 17:17534666231158563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014; 2:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013; 144:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cazzola M, Rogliani P, Calzetta L, et al. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD 2017; 14:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calverley P, Rogliani P, Papi A. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf 2021; 44:273.
          </a>
         </li>
         <li class="breakAll">
          Swinyard EA, Pathak MA. Surface-acting drugs. In: The Pharmacological Basis of Therapeutics, 6th ed, Goodman, Gilman (Eds), Macmillan, New York 1980.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao S, Wilson DB, Brooks RC, Sproule BJ. Acute effects of nebulization of N-acetylcysteine on pulmonary mechanics and gas exchange. Am Rev Respir Dis 1970; 102:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallon AM. Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy. Thorax 1996; 51:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillai K, Mekkawy AH, Akhter J, Morris DL. Effect of Nebulized BromAc on Rheology of Artificial Sputum: Relevance to Muco-Obstructive Respiratory Diseases. Adv Respir Med 2023; 91:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004; 30:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dal Negro RW, Wedzicha JA, Iversen M, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J 2017; 50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calverley PM, Page C, Dal Negro RW, et al. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation. Int J Chron Obstruct Pulmon Dis 2019; 14:2733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogliani P, Matera MG, Page C, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res 2019; 20:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dal Negro RW, Visconti M, Tognella S, Micheletto C. Erdosteine affects eicosanoid production in COPD. Int J Clin Pharmacol Ther 2011; 49:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371:2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng JP, Wen FQ, Bai CX, et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. COPD 2013; 10:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shim C, King M, Williams MH Jr. Lack of effect of hydration on sputum production in chronic bronchitis. Chest 1987; 92:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BARACH AL, BICKERMAN HA, BECK GJ, et al. Induced sputum as a diagnostic technique for cancer of the lungs and for mobilization of retained secretions. Arch Intern Med 1960; 106:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am Rev Respir Dis 1978; 117:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997; 156:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett WD, Henderson AG, Ceppe A, et al. Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis. ERJ Open Res 2020; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taube C, Holz O, Mücke M, et al. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valderramas SR, Atallah AN. Effectiveness and safety of hypertonic saline inhalation combined with exercise training in patients with chronic obstructive pulmonary disease: a randomized trial. Respir Care 2009; 54:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziment I. Pharmacologic therapy of obstructive airway disease. Clin Chest Med 1990; 11:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malerba M, Ponticiello A, Radaeli A, et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavia D, Agnew JE, Glassman JM, et al. Effects of iodopropylidene glycerol on tracheobronchial clearance in stable, chronic bronchitic patients. Eur J Respir Dis 1985; 67:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonelli A, Carraro A, Donati C, Garrubba V. Mucolytic effects of domiodol in tracheostomized patients after total laryngectomy. Double-blind, placebo-controlled, randomized pilot study with four-month follow-up. Arzneimittelforschung 1992; 42:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990; 97:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996; 109:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mezey RJ, Cohn MA, Fernandez RJ, et al. Mucociliary transport in allergic patients with antigen-induced bronchospasm. Am Rev Respir Dis 1978; 118:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aaron SD. Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy. Eur Respir J 2017; 50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehre C, Rushton ZL, Wang B, et al. An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. Am J Respir Crit Care Med 2019; 199:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Addante A, Raymond W, Gitlin I, et al. A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. Eur Respir J 2023; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girod S, Galabert C, Lecuire A, et al. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatr Pulmonol 1992; 13:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Sanctis GT, Tomkiewicz RP, Rubin BK, et al. Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog. Eur Respir J 1994; 7:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anzueto A, Jubran A, Ohar JA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997; 278:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolkove N, Kamel H, Rotaple M, Baltzan MA Jr. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD. Chest 2002; 121:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolini A, Mascardi V, Grecchi B, et al. Comparison of effectiveness of temporary positive expiratory pressure versus oscillatory positive expiratory pressure in severe COPD patients. Clin Respir J 2018; 12:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi S, Yin J, Anderson PK. Lung flute improves symptoms and health status in COPD with chronic bronchitis: A 26 week randomized controlled trial. Clin Transl Med 2014; 3:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cegla UH, Jost HJ, Harten A, et al. [Course of Severe COPD with and without Physiotherapy with the RC-Cornet(R)]. Pneumologie 2002; 56:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alghamdi SM, Alsulayyim AS, Alasmari AM, et al. Oscillatory positive expiratory pressure therapy in COPD (O-COPD): a randomised controlled trial. Thorax 2023; 78:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svenningsen S, Paulin GA, Sheikh K, et al. Oscillatory Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease. COPD 2016; 13:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mascardi V, Grecchi B, Barlascini C, et al. Effectiveness of temporary positive expiratory pressure (T-PEP) at home and at hospital in patients with severe chronic obstructive pulmonary disease. J Thorac Dis 2016; 8:2895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daynes E, Jones AW, Greening NJ, Singh SJ. The Use of Airway Clearance Devices in the Management of Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis of Randomized Controlled Trials. Ann Am Thorac Soc 2021; 18:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alghamdi SM, Barker RE, Alsulayyim ASS, et al. Use of oscillatory positive expiratory pressure (OPEP) devices to augment sputum clearance in COPD: a systematic review and meta-analysis. Thorax 2020; 75:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fink JB, Mahlmeister MJ. High-frequency oscillation of the airway and chest wall. Respir Care 2002; 47:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           dos Santos AP, Guimarães RC, de Carvalho EM, Gastaldi AC. Mechanical behaviors of Flutter VRP1, Shaker, and Acapella devices. Respir Care 2013; 58:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomkiewicz RP, Biviji A, King M. Effects of oscillating air flow on the rheological properties and clearability of mucous gel simulants. Biorheology 1994; 31:511.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1456 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="www.goldcopd.org" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27847895" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7956415" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Task Group on Mucoactive Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17716385" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mucoactive agents for airway mucus hypersecretory diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16528010" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effective mucus clearance is essential for respiratory health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12088546" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Physiology of airway mucus clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22923574" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415249" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Airway mucus: From production to secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17850213" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Structure and function of the polymeric mucins in airways mucus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32559" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The anatomy, physiology, pharmacology and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28877023" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Airway Mucin Concentration as a Marker of Chronic Bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3839090" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Morphological features of the interaction between mucus and surfactant on the bronchial mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503821" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21990373" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36736964" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/304876" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mucus viscoelasticity and mucociliary transport rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6466793" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Influence of rheological properties of human bronchial secretions on the ciliary beat frequency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2611367" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The role of mucus gel viscosity, spinnability, and adhesive properties in clearance by simulated cough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230742" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230742" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9739046" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Coordinated clearance of periciliary liquid and mucus from airway surfaces.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15065840" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/956095" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effect of adrenergic agents and their mode of action on mucociliary clearance in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2878612" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Airway mucus membrane: effects of beta-adrenergic and anticholinergic stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2947458" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effect of ipratropium bromide on airway mucociliary function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1244783" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effects of atropine on velocity of tracheal mucus in anesthetized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2943050" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15136383" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21397483" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3002175" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effects of methylxanthines on airway mucociliary function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7030662" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The effect of oral aminophylline on lung mucociliary clearance in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21272339" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19716960" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1489129" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3726286" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Beclomethasone dipropionate does not affect mucociliary clearance in patients with chronic obstructive lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17935949" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230759" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10623585" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6938381" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effect of mucolytic and expectorant drugs on tracheobronchial clearance in chronic bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35745833" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31107966" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31107966" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17532680" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3294038" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3329530" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10968500" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15581425" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866309" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2866607" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3893512" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effect of oral N-acetylcysteine on mucus clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3817074" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24378052" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36927162" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24621680" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23348146" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28753070" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12765423" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33326056" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33326056" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5427399" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Acute effects of nebulization of N-acetylcysteine on pulmonary mechanics and gas exchange.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8733499" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37102780" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Effect of Nebulized BromAc on Rheology of Artificial Sputum: Relevance to Muco-Obstructive Respiratory Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15553660" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29025888" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31819405" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31133026" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21176724" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Erdosteine affects eicosanoid production in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18555912" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23061828" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3652753" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Lack of effect of hydration on sputum production in chronic bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13796520" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Induced sputum as a diagnostic technique for cancer of the lungs and for mobilization of retained secretions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/637404" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230743" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421364" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421365" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Mucus clearance and lung function in cystic fibrosis with hypertonic saline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32802823" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11734428" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19245725" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effectiveness and safety of hypertonic saline inhalation combined with exercise training in patients with chronic obstructive pulmonary disease: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2205440" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pharmacologic therapy of obstructive airway disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14643168" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3908131" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effects of iodopropylidene glycerol on tracheobronchial clearance in stable, chronic bronchitic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1610421" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Mucolytic effects of domiodol in tracheostomized patients after total laryngectomy. Double-blind, placebo-controlled, randomized pilot study with four-month follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403903" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8620704" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/101106" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Mucociliary transport in allergic patients with antigen-induced bronchospasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29025882" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30212240" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37080569" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1589308" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7995390" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9356001" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11888949" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28665556" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Comparison of effectiveness of temporary positive expiratory pressure versus oscillatory positive expiratory pressure in severe COPD patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25625006" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Lung flute improves symptoms and health status in COPD with chronic bronchitis: A 26 week randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12140795" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : [Course of Severe COPD with and without Physiotherapy with the RC-Cornet(R)].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35948418" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Oscillatory positive expiratory pressure therapy in COPD (O-COPD): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26430763" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Oscillatory Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27867566" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Effectiveness of temporary positive expiratory pressure (T-PEP) at home and at hospital in patients with severe chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32783774" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : The Use of Airway Clearance Devices in the Management of Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32788259" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Use of oscillatory positive expiratory pressure (OPEP) devices to augment sputum clearance in COPD: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12088550" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : High-frequency oscillation of the airway and chest wall.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22906833" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Mechanical behaviors of Flutter VRP1, Shaker, and Acapella devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7833454" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Effects of oscillating air flow on the rheological properties and clearability of mucous gel simulants.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
